{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:43:34Z","timestamp":1791333814517,"version":"4.3.1"},"reference-count":155,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Dengue, caused by the dengue virus (DENV), affects millions of people worldwide every year. This virus has two distinct life cycles, one in the human and another in the mosquito, and both cycles are crucial to be controlled. To control the vector of DENV, the mosquito\n                    <jats:italic>Aedes aegypti<\/jats:italic>\n                    , scientists employed many techniques, which were later proved ineffective and harmful in many ways. Consequently, the attention shifted to the development of a vaccine; researchers have targeted the E protein, a surface protein of the virus and the NS1 protein, an extracellular protein. There are several types of vaccines developed so far, such as live attenuated vaccines, recombinant subunit vaccines, inactivated virus vaccines, viral vectored vaccines, DNA vaccines, and mRNA vaccines. Along with these, scientists are exploring new strategies of developing improved version of the vaccine by employing recombinant DNA plasmid against NS1 and also aiming to prevent the infection by blocking the DENV life cycle inside the mosquitoes. Here, we discussed the aspects of research in the field of vaccines until now and identified some prospects for future vaccine developments.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2024.1362780","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:03:23Z","timestamp":1709165003000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":39,"title":["Approaches of dengue control: vaccine strategies and future aspects"],"prefix":"10.3389","volume":"15","author":[{"given":"Runa","family":"Akter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faria","family":"Tasneem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuvo","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahfuza Afroz","family":"Soma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilias","family":"Georgakopoulos-Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rifat Tasnim","family":"Juthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saiful Arefeen","family":"Sazed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,29]]},"reference":[{"key":"B1","unstructured":"Dengue and severe dengueWorld Health Organization2023"},{"key":"B2","doi-asserted-by":"publisher","first-page":"taw062","DOI":"10.1093\/jtm\/taw062","article-title":"Evidence-based risk assessment and communication: a new global dengue-risk map for travellers and clinicians","volume":"23","author":"Jentes","year":"2016","journal-title":"J Travel Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30518-7","article-title":"Epidemic arboviral diseases: priorities for research and public health","volume":"17","author":"Wilder-Smith","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"tax015","DOI":"10.1093\/jtm\/tax015","article-title":"Imported dengue fever in East London: a 6-year retrospective observational study","volume":"24","author":"Riddell","year":"2017","journal-title":"J Travel Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"tay061","DOI":"10.1093\/jtm\/tay061","article-title":"Dengue infection in international travellers visiting Bali, Indonesia","volume":"25","author":"Masyeni","year":"2018","journal-title":"J Travel Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S0255-0857(21)02943-1","article-title":"Dengue haemorrhagic fever: a global challenge","volume":"22","author":"Chaturvedi","year":"2004","journal-title":"Indian J Med Microbiol"},{"key":"B7","article-title":"Geographical distribution of dengue cases reported worldwid","year":"2021"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.08347","article-title":"The global distribution of the arbovirus vectors Aedes aEgypti and Ae. albopictus","volume":"4","author":"Kraemer","year":"2015","journal-title":"eLife"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01257-06","article-title":"Recent advances in deciphering viral and host determinants of dengue virus replication and pathogenesis","volume":"80","author":"Clyde","year":"2006","journal-title":"J Virol"},{"key":"B10","article-title":"Special programme for research and training in tropical diseases. Dengue: guidelines for diagnosis, treatment","year":"2009","journal-title":"Prev Control"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)12483-7","article-title":"Dengue and dengue haemorrhagic fever","volume":"352","author":"Rigau-P\u00e9rez","year":"1998","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.38.3.1053-1057.2000","article-title":"An antigen capture enzyme-linked immunosorbent assay reveals high levels of the dengue virus protein NS1 in the sera of infected patients","volume":"38","author":"Young Paul","year":"2000","journal-title":"J Clin Microbiol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.mjafi.2014.09.011","article-title":"Discovery of fifth serotype of dengue virus (DENV-5): A new public health dilemma in dengue control","volume":"71","author":"Mustafa","year":"2015","journal-title":"Med J Armed Forces India"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1126\/science.342.6157.415","article-title":"Surprising new dengue virus throws a spanner in disease control efforts","volume":"342","author":"Normile","year":"2013","journal-title":"Science"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.11622\/smedj.2018008","article-title":"Comment on: definitive tests for dengue fever: when and which should I use","volume":"59","author":"Joob","year":"2018","journal-title":"Singapore Med J"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.biotechadv.2010.11.008","article-title":"Review of dengue virus and the development of a vaccine","volume":"29","author":"Murrell","year":"2011","journal-title":"Biotechnol Adv"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1126\/science.131.3407.1102","article-title":"Viruses associated with epidemic hemorrhagic fevers of the Philippines and Thailand","volume":"131","author":"Hammon","year":"1960","journal-title":"Science"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2009.09.024","article-title":"Dengue virus neutralization is modulated by IgG antibody subclass and Fc\u03b3 receptor subtype","volume":"394","author":"Rodrigo","year":"2009","journal-title":"Virology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2012.09.018","article-title":"Neutralization of dengue virus in the presence of Fc receptor-mediated phagocytosis distinguishes serotype-specific from cross-neutralizing antibodies","volume":"96","author":"Wu","year":"2012","journal-title":"Antiviral Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002357","article-title":"Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year","volume":"7","author":"Montoya","year":"2013","journal-title":"PloS Negl Trop Dis"},{"key":"B22","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-642-02215-9_1","article-title":"Prospective cohort studies of dengue viral transmission and severity of disease","volume-title":"Dengue virus","author":"Endy","year":"2010"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00290","article-title":"Human to mosquito transmission of dengue viruses","volume":"5","author":"Carrington","year":"2014","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.pt.2015.09.009","article-title":"Mosquito defense strategies against viral infection","volume":"32","author":"Cheng","year":"2016","journal-title":"Trends Parasitol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"111609","DOI":"10.1016\/j.indcrop.2019.111609","article-title":"Chemical composition and repellent activity of native plants essential oils against dengue mosquito, Aedes aEgypti","volume":"140","author":"Azeem","year":"2019","journal-title":"Ind Crops Products"},{"key":"B26","volume-title":"Dengue: guidelines for diagnosis, treatment, prevention and control.","year":"2009"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-4758(99)01605-1","article-title":"Should DDT be banned by international treaty","volume":"16","author":"Curtis","year":"2000","journal-title":"Parasitol Today"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph8051402","article-title":"Pesticide exposure, safety issues, and risk assessment indicators","volume":"8","author":"Damalas","year":"2011","journal-title":"Int J Environ Res Public Health"},{"key":"B29","doi-asserted-by":"publisher","first-page":"6619175","DOI":"10.1155\/2021\/6619175","article-title":"A Challenge for a Unique Dengue Vector Control Programme: Assessment of the Spatial Variation of Insecticide Resistance Status amongst Aedes aEgypti and Aedes albopictus Populations in Gampaha District, Sri Lanka","volume":"2021","author":"Dalpadado","year":"2021","journal-title":"BioMed Res Int"},{"key":"B30","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/S2222-1808(14)60319-4","article-title":"Wolbachia-a foe for mosquitoes","volume":"4","author":"Guruprasad","year":"2014","journal-title":"Asian Pacific J Trop Dis"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001760","article-title":"Refining the global spatial limits of dengue virus transmission by evidence-based consensus","volume":"6","author":"Brady","year":"2012","journal-title":"PloS Negl Trop Dis"},{"key":"B32","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.antiviral.2008.06.010","article-title":"Mouse models of dengue virus infection and disease","volume":"80","author":"Yauch","year":"2008","journal-title":"Antiviral Res"},{"key":"B33","first-page":"367","article-title":"Recherches experimentales sur la dengue","volume":"44","author":"Blanc","year":"1930","journal-title":"Ann l'Inst. Pasteur"},{"key":"B34","article-title":"Experimental studies of dengue","volume":"44","author":"Simmons","year":"1931","journal-title":"Philippine J Sci"},{"key":"B35","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-12-625380-1.50010-2","volume-title":"Immunological parameters of togavirus disease syndromes","author":"Halstead","year":"1980"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1126\/science.239.4839.476","article-title":"Pathogenesis of dengue: challenges to molecular biology","volume":"239","author":"Halstead","year":"1988","journal-title":"Science"},{"key":"B37","doi-asserted-by":"publisher","first-page":"304ra142","DOI":"10.1126\/scitranslmed.aaa3863","article-title":"Dengue virus NS1 protein activates cells via Toll-like receptor 4 and disrupts endothelial cell monolayer integrity","volume":"7","author":"Modhiran","year":"2015","journal-title":"Sci Trans Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/v4010062","article-title":"Animal models of dengue virus infection","volume":"4","author":"Zompi","year":"2012","journal-title":"Viruses"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.7774\/cevr.2017.6.2.104","article-title":"Animal models for dengue vaccine development and testing","volume":"6","author":"Na","year":"2017","journal-title":"Clin Exp Vaccine Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-022-00531-z","article-title":"Dengue vaccines: an update","volume":"36","author":"Torres-Flores","year":"2022","journal-title":"BioDrugs"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(00)00040-2","article-title":"Live attenuated tetravalent dengue vaccine","volume":"18","author":"Bhamarapravati","year":"2000","journal-title":"Vaccine"},{"key":"B42","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4269\/ajtmh.2003.69.6_suppl.0690005","article-title":"Biologic properties of dengue viruses following serial passage in primary dog kidney cells: studies at the University of Hawaii","volume":"69","author":"Halstead","year":"2003","journal-title":"Am J Trop Med hygiene"},{"key":"B43","volume-title":"Dengue vaccine safety update. WHO weekly epidemiological report","year":"2018"},{"key":"B44","doi-asserted-by":"publisher","first-page":"24","DOI":"10.4269\/ajtmh.2003.69.6_suppl.0690024","article-title":"Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates","volume":"69","author":"Sun","year":"2003","journal-title":"Am J Trop Med hygiene"},{"key":"B45","doi-asserted-by":"publisher","first-page":"73","DOI":"10.4269\/ajtmh.2012.12-0361","article-title":"A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults","volume":"88","author":"Thomas","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.12.5139","article-title":"Infectious RNA transcribed from stably cloned full-length cDNA of dengue type 4 virus","volume":"88","author":"Lai","year":"1991","journal-title":"Proc Natl Acad Sci"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.71.7.5366-5374.1997","article-title":"Infectious RNA transcripts from full-length dengue virus type 2 cDNA clones made in yeast","volume":"71","author":"Polo","year":"1997","journal-title":"J Virol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)11276-1","article-title":"The future of dengue vaccines","volume":"360","author":"Halstead","year":"2002","journal-title":"Lancet"},{"key":"B49","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/2051013613507862","article-title":"Latest developments and future directions in dengue vaccines","volume":"2","author":"Thisyakorn","year":"2014","journal-title":"Ther Adv Vaccines"},{"key":"B50","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3390\/vaccines8010063","article-title":"A review on dengue vaccine development","volume":"8","author":"Deng","year":"2020","journal-title":"Vaccines"},{"key":"B51","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.enzmictec.2012.05.005","article-title":"Using recombinant DNA technology for the development of live-attenuated dengue vaccines","volume":"51","author":"Lee","year":"2012","journal-title":"Enzyme Microbial Technol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1586\/14760584.2016.1128328","article-title":"A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone","volume":"15","author":"Osorio","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"B53","article-title":"Transcription of infectious yellow fever RNA from full-length cDNA templates produced by in vitro ligation","volume":"1","author":"Rice","year":"1989","journal-title":"New biologist"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.12.5477-5485.2000","article-title":"Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates","volume":"74","author":"Guirakhoo","year":"2000","journal-title":"J Virol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.9.4761-4775.2004","article-title":"Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates","volume":"78","author":"Guirakhoo","year":"2004","journal-title":"J Virol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506223","article-title":"Efficacy and long-term safety of a dengue vaccine in regions of endemic disease","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"New Engl J Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2016.1134329","article-title":"Financing dengue vaccine introduction in the Americas: challenges and opportunities","volume":"15","author":"Constenla","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.12.6172-6184.2002","article-title":"Neuroblastoma cell-adapted yellow fever 17D virus: characterization of a viral variant associated with persistent infection and decreased virus spread","volume":"76","author":"Vlaycheva Leonsia","year":"2002","journal-title":"J Virol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.06.094","article-title":"From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine","volume":"29","author":"Guy","year":"2011","journal-title":"Vaccine"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61428-7","article-title":"Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial","volume":"380","author":"Sabchareon","year":"2012","journal-title":"Lancet"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1086\/649916","article-title":"A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults","volume":"201","author":"Morrison","year":"2010","journal-title":"J Infect Dis"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a tetravalent dengue vaccine in children in Latin America","volume":"372","author":"Villar","year":"2014","journal-title":"N Engl J Med."},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial","volume":"384","author":"Capeding","year":"2014","journal-title":"Lancet."},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61510-4","article-title":"Dengue vaccine development: a 75% solution","volume":"380","author":"Halstead","year":"2012","journal-title":"Lancet"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2017.1335201","article-title":"A recombinant live attenuated tetravalent vaccine for the prevention of dengue","volume":"16","author":"Guy","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.09.063","article-title":"Dengue vaccine: WHO position paper, September 2018 \u2013 Recommendations","volume":"37","year":"2019","journal-title":"Vaccine"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.07.023","article-title":"Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine","volume":"29","author":"Durbin","year":"2011","journal-title":"Vaccine"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.70.6.3930-3937.1996","article-title":"Dengue type 4 virus mutants containing deletions in the 3' noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys","volume":"70","author":"Men","year":"1996","journal-title":"J Virol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3390\/v9060137","article-title":"The 5' and 3' Untranslated regions of the flaviviral genome","volume":"9","author":"Ng","year":"2017","journal-title":"Viruses"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2001.65.405","article-title":"Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region","volume":"65","author":"Durbin","year":"2001","journal-title":"Am J Trop Med hygiene"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.20.9731-9740.2001","article-title":"Chemical mutagenesis of dengue virus type 4 yields mutant viruses which are temperature sensitive in vero cells or human liver cells and attenuated in mice","volume":"75","author":"Blaney Joseph","year":"2001","journal-title":"J Virol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.2.525-531.2002","article-title":"Paired charge-to-alanine mutagenesis of dengue virus type 4 NS5 generates mutants with temperature-sensitive, host range, and mouse attenuation phenotypes","volume":"76","author":"Hanley Kathryn","year":"2002","journal-title":"J Virol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2004.02.031","article-title":"Introduction of mutations into the non-structural genes or 3\u2032 untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunity","volume":"22","author":"Hanley","year":"2004","journal-title":"Vaccine"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis936","article-title":"A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: A randomized, double-blind clinical trial","volume":"207","author":"Durbin","year":"2013","journal-title":"J Infect Dis"},{"key":"B75","doi-asserted-by":"publisher","first-page":"330ra36","DOI":"10.1126\/scitranslmed.aaf1517","article-title":"The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model","volume":"8","author":"Kirkpatrick","year":"2016","journal-title":"Sci Trans Med"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv082","article-title":"Robust and balanced immune responses to all 4 dengue virus serotypes following administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy, flavivirus-naive adults","volume":"212","author":"Kirkpatrick","year":"2015","journal-title":"J Infect Dis"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2016.1115727","article-title":"Development of TV003\/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD\u2122 vaccine","volume":"15","author":"Whitehead","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000109289.55856.27","article-title":"Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children","volume":"23","author":"Sabchareon","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2008.78.426","article-title":"Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children","volume":"78","author":"Simasathien","year":"2008","journal-title":"Am J Trop Med hygiene"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.11.072","article-title":"Immunogenicity and efficacy of chimeric dengue vaccine (DENVax) formulations in interferon-deficient AG129 mice","volume":"30","author":"Brewoo","year":"2012","journal-title":"Vaccine"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/174.6.1176","article-title":"Development of a purified, inactivated, dengue-2 virus vaccine prototype in vero cells: immunogenicity and protection in mice and rhesus monkeys","volume":"174","author":"Putnak","year":"1996","journal-title":"J Infect Dis"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.03.042","article-title":"An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model","volume":"23","author":"Robert Putnak","year":"2005","journal-title":"Vaccine"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1086\/503372","article-title":"Protection of Rhesus Monkeys against Dengue Virus Challenge after Tetravalent Live Attenuated Dengue Virus Vaccination","volume":"193","author":"Sun","year":"2006","journal-title":"J Infect Dis"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1007\/s00103-019-03060-3","article-title":"Dengue vaccine development: status and future","volume":"63","author":"Wilder-Smith","year":"2020","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2009.10.023","article-title":"Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy","volume":"396","author":"Simmons","year":"2010","journal-title":"Virology"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1089\/vim.2000.13.179","article-title":"T-cell activation and induction of antibodies and memory T cells by immunization with inactivated Japanese encephalitis vaccine","volume":"13","author":"Aihara","year":"2000","journal-title":"Viral Immunol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro1690","article-title":"Prospects for a dengue virus vaccine","volume":"5","author":"Whitehead","year":"2007","journal-title":"Nat Rev Microbiol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01919","article-title":"Recent developments in recombinant protein\u2013based dengue vaccines","volume":"9","author":"Tripathi","year":"2018","journal-title":"Front Immunol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.07.006","article-title":"Immunogenicity of a recombinant envelope domain III protein of dengue virus type-4 with various adjuvants in mice","volume":"26","author":"Babu","year":"2008","journal-title":"Vaccine"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1139\/w11-137","article-title":"Eliciting cross-neutralizing antibodies in mice challenged with a dengue virus envelope domain III expressed in Escherichia coli","volume":"58","author":"Yang","year":"2012","journal-title":"Can J Microbiol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.01.041","article-title":"Recombinant lipidated dengue-4 envelope protein domain III elicits protective immunity","volume":"32","author":"Chiang","year":"2014","journal-title":"Vaccine"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.01.009","article-title":"Recombinant lipidated dengue-3 envelope protein domain III stimulates broad immune responses in mice","volume":"34","author":"Chiang","year":"2016","journal-title":"Vaccine"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00364","article-title":"Spirochetal lipoproteins and immune evasion","volume":"8","author":"Christodoulides","year":"2017","journal-title":"Front Immunol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1111\/1348-0421.12140","article-title":"Evaluation in mice of the immunogenicity and protective efficacy of a tetravalent subunit vaccine candidate against dengue virus","volume":"58","author":"Lazo","year":"2014","journal-title":"Microbiol Immunol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0086573","article-title":"Induction of neutralizing antibodies against four serotypes of dengue viruses by mixBiEDIII, a tetravalent dengue vaccine","volume":"9","author":"Zhao","year":"2014","journal-title":"PloS One"},{"key":"B96","doi-asserted-by":"publisher","first-page":"112304","DOI":"10.1016\/j.biopha.2021.112304","article-title":"Targets and strategies for vaccine development against dengue viruses","volume":"144","author":"Wang","year":"2021","journal-title":"BioMed Pharmacother"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1186\/s12934-018-0876-0","article-title":"Comparative immunogenicity of preparations of yeast-derived dengue oral vaccine candidate","volume":"17","author":"Bal","year":"2018","journal-title":"Microbial Cell Factories"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.01.022","article-title":"Development of a recombinant tetravalent dengue virus vaccine: Immunogenicity and efficacy studies in mice and monkeys","volume":"28","author":"Clements","year":"2010","journal-title":"Vaccine"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.06.067","article-title":"Preclinical development of a dengue tetravalent recombinant subunit vaccine: Immunogenicity and protective efficacy in nonhuman primates","volume":"33","author":"Govindarajan","year":"2015","journal-title":"Vaccine"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1111\/pbi.12741","article-title":"Molecular engineering and plant expression of an immunoglobulin heavy chain scaffold for delivery of a dengue vaccine candidate","volume":"15","author":"Kim","year":"2017","journal-title":"Plant Biotechnol J"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1995.53.432","article-title":"Murine immunoglobulin G subclass responses following immunization with live dengue virus or a recombinant dengue envelope protein","volume":"53","author":"Smucny","year":"1995","journal-title":"Am J Trop Med Hygiene"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1298473","DOI":"10.1155\/2016\/1298473","article-title":"Immunogenicity of biotherapeutics: causes and association with posttranslational modifications","volume":"2016","author":"Kuriakose","year":"2016","journal-title":"J Immunol Res"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-800098-4.00007-6","article-title":"Dengue virus vaccine development","volume":"88","author":"Yauch","year":"2014","journal-title":"Adv Virus Res"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.61.12.4019-4022.1987","article-title":"Expression of dengue virus structural proteins and nonstructural protein NS1 by a recombinant vaccinia virus","volume":"61","author":"Zhao","year":"1987","journal-title":"J Virol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(00)00121-3","article-title":"Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge","volume":"18","author":"Men","year":"2000","journal-title":"Vaccine"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.23.12907-12913.2003","article-title":"Replication-defective adenoviral vaccine vector for the induction of immune responses to dengue virus type 2","volume":"77","author":"Jaiswal","year":"2003","journal-title":"J Virol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1472-6750-7-10","article-title":"An adenovirus prime\/plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypes","volume":"7","author":"Khanam","year":"2007","journal-title":"BMC Biotechnol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.07.073","article-title":"An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity","volume":"27","author":"Khanam","year":"2009","journal-title":"Vaccine"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00330-06","article-title":"Two complex, adenovirus-based vaccines that together induce immune responses to all four dengue virus serotypes","volume":"14","author":"Holman David","year":"2007","journal-title":"Clin Vaccine Immunol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.2.914-922.2000","article-title":"Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis","volume":"74","author":"Macdonald Gene","year":"2000","journal-title":"J Virol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0600287103","article-title":"Mucosal and systemic adjuvant activity of alphavirus replicon particles","volume":"103","author":"Thompson","year":"2006","journal-title":"Proc Natl Acad Sci"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00996-07","article-title":"A heterologous DNA prime-Venezuelan equine encephalitis virus replicon particle boost dengue vaccine regimen affords complete protection from virus challenge in cynomolgus macaques","volume":"81","author":"Chen","year":"2007","journal-title":"J Virol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02298-12","article-title":"An alphavirus vector-based tetravalent dengue vaccine induces a rapid and protective immune response in macaques that differs qualitatively from immunity induced by live virus infection","volume":"87","author":"White Laura","year":"2013","journal-title":"J Virol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.05.053","article-title":"A tetravalent alphavirus-vector based dengue vaccine provides effective immunity in an early life mouse model","volume":"32","author":"Khalil","year":"2014","journal-title":"Vaccine"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(97)00215-6","article-title":"Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice","volume":"15","author":"Kochel","year":"1997","journal-title":"Vaccine"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(99)00570-8","article-title":"Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein","volume":"18","author":"Raviprakash","year":"2000","journal-title":"Vaccine"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.11.050","article-title":"Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial","volume":"29","author":"Beckett","year":"2011","journal-title":"Vaccine"},{"key":"B118","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s007050050348","article-title":"Protective efficacy of a dengue 2 DNA vaccine in mice and the effect of CpG immuno-stimulatory motifs on antibody responses","volume":"143","author":"Porter","year":"1998","journal-title":"Arch Virol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2001.65.420","article-title":"Characterization of antibody responses to combinations of a dengue-2 DNA and dengue-2 recombinant subunit vaccine","volume":"65","author":"Simmons","year":"2001","journal-title":"Am J Trop Med hygiene"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00284-06","article-title":"Characterization of antibody responses to combinations of a dengue virus type 2 DNA vaccine and two dengue virus type 2 protein vaccines in rhesus macaques","volume":"80","author":"Simmons","year":"2006","journal-title":"J Virol"},{"key":"B121","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1006\/viro.2001.1136","article-title":"Synergistic neutralizing antibody response to a dengue virus type 2 DNA vaccine by incorporation of lysosome-associated membrane protein sequences and use of plasmid expressing GM-CSF","volume":"290","author":"Raviprakash","year":"2001","journal-title":"Virology"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00059","article-title":"Dendritic cell targeting using a DNA vaccine induces specific antibodies and CD4+ T cells to the dengue virus envelope protein domain III","volume":"10","author":"Zaneti","year":"2019","journal-title":"Front Immunol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1042\/BA20080074","article-title":"Dengue-4 envelope domain III fused twice within the meningococcal P64k protein carrier induces partial protection in mice","volume":"52","author":"Lazo","year":"2009","journal-title":"Biotechnol Appl Biochem"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.17-0416","article-title":"Safety and immunogenicity of a tetravalent dengue DNA vaccine administered with a cationic lipid-based adjuvant in a phase 1 clinical trial","volume":"98","author":"Danko","year":"2018","journal-title":"Am J Trop Med Hygiene"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.07.019","article-title":"Development of dengue DNA vaccines","volume":"29","author":"Danko","year":"2011","journal-title":"Vaccine"},{"key":"B126","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/emi.2016.74","article-title":"Vaccines and immunization strategies for dengue prevention","volume":"5","author":"Liu","year":"2016","journal-title":"Emerging Microbes Infections"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1126\/science.1247749","article-title":"Flavivirus NS1 structures reveal surfaces for associations with membranes and the immune system","volume":"343","author":"Akey","year":"2014","journal-title":"Science"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-69-8-2101","article-title":"Synergistic interactions of anti-NS1 monoclonal antibodies protect passively immunized mice from lethal challenge with dengue 2 virus","volume":"69","author":"Henchal","year":"1988","journal-title":"J Gen Virol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-68-3-853","article-title":"Protection of mice against dengue 2 virus encephalitis by immunization with the dengue 2 virus non-structural glycoprotein NS1","volume":"68","author":"Schlesinger","year":"1987","journal-title":"J Gen Virol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.12.034","article-title":"Protective immunity to DENV2 after immunization with a recombinant NS1 protein using a genetically detoxified heat-labile toxin as an adjuvant","volume":"30","author":"Amorim","year":"2012","journal-title":"Vaccine"},{"key":"B131","doi-asserted-by":"publisher","first-page":"304ra141","DOI":"10.1126\/scitranslmed.aaa3787","article-title":"Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination","volume":"7","author":"Beatty","year":"2015","journal-title":"Sci Trans Med"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(94)00059-V","article-title":"Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection","volume":"13","author":"Srivastava","year":"1995","journal-title":"Vaccine"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2012.11.007","article-title":"Preliminary evaluation of DNA vaccine candidates encoding dengue-2 prM\/E and NS1: Their immunity and protective efficacy in mice","volume":"54","author":"Lu","year":"2013","journal-title":"Mol Immunol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.08.022","article-title":"DNA vaccine against the non-structural 1 protein (NS1) of dengue 2 virus","volume":"24","author":"Costa","year":"2006","journal-title":"Vaccine"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(03)00310-4","article-title":"Evaluation of protective efficacy and immune mechanisms of using a non-structural protein NS1 in DNA vaccine against dengue 2 virus in mice","volume":"21","author":"Wu","year":"2003","journal-title":"Vaccine"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.64.9.4356-4363.1990","article-title":"Immunization of mice with recombinant vaccinia virus expressing authentic dengue virus nonstructural protein NS1 protects against lethal dengue virus encephalitis","volume":"64","author":"Falgout","year":"1990","journal-title":"J Virol"},{"key":"B137","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jfma.2012.11.006","article-title":"Autoimmunity in dengue pathogenesis","volume":"112","author":"Wan","year":"2013","journal-title":"J Formosan Med Assoc"},{"key":"B138","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/1475-2875-6-107","article-title":"Transmission-blocking activity induced by malaria vaccine candidates Pfs25\/Pvs25 is a direct and predictable function of antibody titer","volume":"6","author":"Miura","year":"2007","journal-title":"Malaria J"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0006352","article-title":"A potent malaria transmission blocking vaccine based on codon harmonized full length pfs48\/45 expressed in escherichia coli","volume":"4","author":"Chowdhury","year":"2009","journal-title":"PloS One"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2017.1276833","article-title":"Towards clinical development of a Pfs48\/45-based transmission blocking malaria vaccine","volume":"16","author":"Theisen","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003931","article-title":"Transmission-blocking antibodies against mosquito C-type lectins for dengue prevention","volume":"10","author":"Liu","year":"2014","journal-title":"PloS Pathog"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005202","article-title":"Dengue virus infection of aedes aEgypti requires a putative cysteine rich venom protein","volume":"11","author":"Londono-Renteria","year":"2015","journal-title":"PloS Pathog"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02482-20","article-title":"A dengue virus serotype 1 mRNA-LNP vaccine elicits protective immune responses","volume":"95","author":"Wollner Clayton","year":"2021","journal-title":"J Virol"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2020.07.013","article-title":"Modified mRNA-LNP Vaccines Confer Protection against Experimental DENV-2 Infection in Mice","volume":"18","author":"Zhang","year":"2020","journal-title":"Mol Ther - Methods Clin Dev"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.840104","article-title":"Current development and challenges of tetravalent live-attenuated dengue vaccines","volume":"13","author":"Hou","year":"2022","journal-title":"Front Immunol"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.14-0625","article-title":"A phase II, randomized, safety and immunogenicity trial of a re-derived, live-attenuated dengue virus vaccine in healthy children and adults living in Puerto Rico","volume":"93","author":"Bauer","year":"2015","journal-title":"Am J Trop Med Hyg"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.17-0627","article-title":"Phase I randomized study of a tetravalent dengue purified inactivated vaccine in healthy adults from Puerto Rico","volume":"98","author":"Diaz","year":"2018","journal-title":"Am J Trop Med Hyg"},{"key":"B148","doi-asserted-by":"publisher","first-page":"001831","DOI":"10.1099\/jgv.0.001831","article-title":"Challenges on the development of a dengue vaccine: a comprehensive review of the state of the art","volume":"104","author":"Pintado Silva","year":"2023","journal-title":"J Gen Virol"},{"key":"B149","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/ITT","article-title":"Immunoinformatics and vaccine development: an overview","volume":"9","author":"Oli","year":"2020","journal-title":"Immunotargets Ther"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.2174\/157340911795677602","article-title":"Molecular docking: a powerful approach for structure-based drug discovery","volume":"7","author":"Meng","year":"2011","journal-title":"Curr Comput Aided Drug Des"},{"key":"B151","doi-asserted-by":"publisher","first-page":"104728","DOI":"10.1016\/j.micpath.2020.104728","article-title":"Immunoinformatics designed T cell multi epitope dengue peptide vaccine derived from non structural proteome","volume":"150","author":"Krishnan","year":"2021","journal-title":"Microb Pathog"},{"key":"B152","doi-asserted-by":"publisher","first-page":"13911","DOI":"10.3390\/ijms232213911","article-title":"Engineering Modified mRNA-Based Vaccine against Dengue Virus Using Computational and Reverse Vaccinology Approaches","volume":"23","author":"Mukhtar","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B153","doi-asserted-by":"publisher","first-page":"9232","DOI":"10.1038\/s41598-017-09199-w","article-title":"Exploring dengue genome to construct a multi-epitope based subunit vaccine by utilizing immunoinformatics approach to battle against dengue infection","volume":"7","author":"Ali","year":"2017","journal-title":"Sci Rep"},{"key":"B154","doi-asserted-by":"publisher","first-page":"19707","DOI":"10.1038\/s41598-021-99227-7","article-title":"Immunoinformatics design of a novel epitope-based vaccine candidate against dengue virus","volume":"11","author":"Fadaka","year":"2021","journal-title":"Sci Rep"},{"key":"B155","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3390\/membranes12020231","article-title":"Structures and dynamics of dengue virus nonstructural membrane proteins","volume":"12","author":"Li","year":"2022","journal-title":"Membranes"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1362780\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:03:30Z","timestamp":1709165010000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1362780\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,29]]},"references-count":155,"alternative-id":["10.3389\/fimmu.2024.1362780"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1362780","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,29]]},"article-number":"1362780"}}